



PART 2

Regulation of IL-6 Signaling

# The correct response of the target cell to cytokines is crucial

Serge Haan, Habilitation 2005



2003

## REVIEW ARTICLE

# Principles of interleukin (IL)-6-type cytokine signalling and its regulation<sup>1</sup>

Peter C. HEINRICH<sup>2</sup>, Iris BEHRMANN, Serge HAAN, Heike M. HERMANNNS, Gerhard MÜLLER-NEWEN and Fred SCHAPER

Institut für Biochemie, RWTH Aachen, Universitätsklinikum, Pauwelsstrasse 30, D-52074 Aachen, Germany

1756 citations (2018)

The IL (interleukin)-6-type cytokines IL-6, IL-11, LIF (leukaemia inhibitory factor), OSM (oncostatin M), ciliary neurotrophic factor, cardiotrophin-1 and cardiotrophin-like cytokine are an important family of mediators involved in the regulation of the acute-phase response to injury and infection. Besides their functions in inflammation and the immune response, these cytokines play also a crucial role in haematopoiesis, liver and neuronal regeneration, embryonal development and fertility. Dysregulation of IL-6-type cytokine signalling contributes to the onset and maintenance of several diseases, such as rheumatoid arthritis, inflammatory bowel disease, osteoporosis, multiple sclerosis and various types of cancer (e.g. multiple myeloma and prostate cancer). IL-6-type cytokines exert their action via the signal transducers gp (glycoprotein) 130, LIF receptor and OSM receptor leading to the activation of the JAK/STAT (Janus kinase/signal

transducer and activator of transcription) and MAPK (mitogen-activated protein kinase) cascades. This review focuses on recent progress in the understanding of the molecular mechanisms of IL-6-type cytokine signal transduction. Emphasis is put on the termination and modulation of the JAK/STAT signalling pathway mediated by tyrosine phosphatases, the SOCS (suppressor of cytokine signalling) feedback inhibitors and PIAS (protein inhibitor of activated STAT) proteins. Also the cross-talk between the JAK/STAT pathway with other signalling cascades is discussed.

Key words: cytokine signalling, glycoprotein 130 (gp 130) interleukin-6 (IL-6), Janus kinase (JAK), mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription (STAT).

# Outline: Interleukin-6 signal transduction and its regulation



## Part 1: Molecular mechanisms of IL-6 signal transduction

## Part 2: Regulation of IL-6 signal transduction

- **Half-lives of the signaling components**
- Polar expression of IL-6 receptor- $\alpha$  (gp80)
- IL-6 receptor- $\alpha$  shedding
- Internalization of the ligand/IL-6 receptor complex (desensitisation)
- Phosphotyrosine-phosphatase SHP2 deactivates receptors, JAKs and STAT3
- SOCS proteins (suppressors of cytokine signaling) are feedback inhibitors
- Protein inhibitors of activated STATs (PIAS)
- Cross-talks between JAK/STAT signaling and proinflammatory cytokines (IL-1, TNF $\alpha$ )
  - STAT3 and NF- $\kappa$ B compete for an overlapping response element
  - IL-1 stabilizes SOCS3-mRNA
  - IL-1 accelerates the internalization of the signal transducer gp130






# Structural organization of various IL-6-type cytokine signaling components



- CBM Cytokine Binding Module
- ESS Extended SH2 Subdomain
- FERM 4.1/Ezrin/Radixin/Moesin
- FNIII Fibronectin type III
- KIR Kinase Inhibitory Region
- PTB Phosphotyrosine Binding
- SH2 Src Homology 2
- TM Transmembrane

## Half-lives of proteins involved in IL-6-type cytokine signaling



COS-7 cells were pulse-labelled with [<sup>35</sup>S]methionine/cysteine and chased for the times indicated (A, 0.25±12 h; B and C, 0.5±72 h).

## Calculated half-lives of IL-6 signaling components

Protein	Half-life [h]	Protein	Half-life [h]
gp80 (IL-6R $\alpha$ )	2.5	STAT3 $\alpha$	8.5
gp130	2.5	STAT3 $\beta$	4.5
Jak1	3.2	STAT3 $\Delta$ 715	8.5
Jak2	1.9		
Tyk2	2.0		
SOCS1	1.5	STAT1	16.0
SOCS2	1.0	SHP2	18.0-20.0
SOCS3	1.6		

STAT3 $\beta$  is a splice variant of STAT3 $\alpha$  lacking the 55 C-terminal amino acids which are substituted by seven STAT3 $\beta$ -specific amino acids.

STAT3  $\Delta$ 715 = STAT3 deletion mutant

Gerhartz et al. *Eur. J. Biochem.* 223, 265-274 (1994) [48 citations](#) (07/2022)

Siewert et al. *Eur. J. Biochem.* 265, 251-257 (1999) [93 citations](#) (07/2022)


# Outline: Interleukin-6 signal transduction and its regulation

## Part 1: Molecular mechanisms of IL-6 signal transduction


## Part 2: Regulation of IL-6 signal transduction

- Half-lives of the signaling components
- **Polar expression of IL-6 receptor- $\alpha$  (gp80)**
- IL-6 receptor- $\alpha$  shedding
- Internalization of the ligand/IL-6 receptor complex (desensitisation)
- Phosphotyrosine-phosphatase SHP2 deactivates receptors, JAKs and STAT3
- SOCS proteins (suppressors of cytokine signaling) are feedback inhibitors
- Protein inhibitors of activated STATs (PIAS)
- Cross-talks between JAK/STAT signaling and proinflammatory cytokines (IL-1, TNF $\alpha$ )
  - STAT3 and NF- $\kappa$ B compete for an overlapping response element
  - IL-1 stabilizes SOCS3-mRNA
  - IL-1 accelerates the internalization of the signal transducer gp130


IL-6 receptor  $\alpha$  chain:  
What is the function of the cytoplasmic part?



IL-6 receptor  $\alpha$  chain:  
What is the function of the cytoplasmic part?



IL-6 receptor  $\alpha$  chain:  
What is the function of the cytoplasmic part?





# The cytoplasmic domain of the interleukin-6 receptor gp80 mediates its basolateral sorting in polarized Madin-Darby canine kidney cells


25 citations (07/2022)

**Astrid S. Martens, Johannes G. Bode, Peter C. Heinrich and Lutz Graeve\***

Institute of Biochemistry, Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule, Pauwelsstrasse 30, 52074 Aachen, Germany


\*Author for correspondence (e-mail: lutz.graeve@post.rwth-aachen.de)

*Accepted 1 August; published on WWW 4 October 2000*






# Polar expression of gp80wt and deletion mutants in MDCK cells




# Basolateral expression of gp80wt in stably transfected MDCK cells


xy



basolateral marker




gp80wt




overlay

xz




# Apical expression of gp80 $\Delta$ CD in stably transfected MDCK cells


xy



basolateral marker




gp80 $\Delta$ CD



overlay

xz






# Outline: Interleukin-6 signal transduction and its regulation

## Part 1: Molecular mechanisms of IL-6 signal transduction

## Part 2: Regulation of IL-6 signal transduction

- Half-lives of the signaling components
- Polar expression of IL-6 receptor- $\alpha$  (gp80)
- **IL-6 receptor- $\alpha$  shedding**
- Internalization of the ligand/IL-6 receptor complex (desensitisation)
- Phosphotyrosine-phosphatase SHP2 deactivates receptors, JAKs and STAT3
- SOCS proteins (suppressors of cytokine signaling) are feedback inhibitors
- Protein inhibitors of activated STATs (PIAS)
- Cross-talks between JAK/STAT signaling and proinflammatory cytokines (IL-1, TNF $\alpha$ )
  - STAT3 and NF- $\kappa$ B compete for an overlapping response element
  - IL-1 stabilizes SOCS3-mRNA
  - IL-1 accelerates the internalization of the signal transducer gp130

# Regulation of IL-6 receptor-mediated signaling by limited proteolysis (shedding)




**A membrane-bound protease:**

**ADAM17 (A Disintegrin and Metalloproteinase)  $\equiv$  TACE (TNF $\alpha$  converting enzyme) has been identified**

# Regulation of IL-6 receptor-mediated signaling by limited proteolysis (shedding)


- PMA (phorbol ester)/PKC (protein kinase C)
- apoptosis
- FMLP (N-formyl-met-leu-phe)
- CRP (C-reactive protein)



**A membrane-bound protease:**

**ADAM17 (A Disintegrin and Metalloproteinase)  $\equiv$  TACE (TNF $\alpha$  converting enzyme) has been identified**

# Agonistic action of the complex of IL-6/soluble-IL-6-receptor and trans-signaling between IL-6-responsive and non-responsive cells



Rose-John & Heinrich (1994), *Biochem. J.*, 300, 281-90

[671 citations](#) (07/2022)

The shedding protease is activated by PKC

Müllberg et al. (1993), *Eur. J. Immunol.*, 23, 473-80

[433 citations](#) (07/2022)

Müllberg et al. (1994), *J. Immunol.*, 152, 4958-68

[237 citations](#) (07/2022)

cleavage site

Increased IL-6 and soluble IL-6 receptor- $\alpha$  levels are found in serum and synovial fluid from patients with rheumatoid arthritis (RA)

Serum				
	IL-6 (ng/ml)	sol IL-6R $\alpha$ (ng/ml)	sol gp130 (ng/ml)	refs
Control	28	28	345	Keul et al. (1998)
RA	78	38	375	Keul et al. (1998)
	51	29	251	Richards et al. (2006)
Synovial fluid				
RA	6.4	15	250	Richards et al. (2006)



1998

# Soluble IL-6 Receptor Potentiates the Antagonistic Activity of Soluble gp130 on IL-6 Responses<sup>1</sup>

130 citations (07/2022)

Gerhard Müller-Newen,\* Andrea Küster,\* Ulrike Hemmann,\* Radovan Keul,\*  
Ursula Horsten,\* Astrid Martens,\* Lutz Graeve,\* John Wijdenes,<sup>†</sup> and Peter C. Heinrich<sup>2\*</sup>

Soluble receptors for several cytokines have been detected in body fluids and are believed to modulate the cytokine response by binding the ligand and thereby reducing its bioavailability. In the case of IL-6, the situation is more complex. The receptor consists of two components, including a ligand-binding  $\alpha$ -subunit (IL-6R, gp80, or CD126), which in its soluble (s) form (sIL-6R) acts agonistically by making the ligand accessible to the second subunit, the signal transducer gp130 (CD130). Soluble forms of both receptor subunits are present in human blood. Gel filtration of iodinated IL-6 that had been incubated with human serum revealed that IL-6 is partially trapped in IL-6/sIL-6R/sgp130 ternary complexes. sgp130 from human plasma was enriched by immunoaffinity chromatography and identified as a 100-kDa protein. Functionally equivalent rsgp130 was produced in baculovirus-infected insect cells to study its antagonistic potential on four different cell types. It was found that in situations in which cells lacking membrane-bound IL-6R were stimulated with IL-6/sIL-6R complexes, sgp130 was a much more potent antagonist than it was on IL-6R-positive cells stimulated with IL-6 alone. In the latter case, the neutralizing activity of sgp130 could be markedly enhanced by addition of sIL-6R. As a consequence of these findings, sIL-6R of human plasma must be regarded as an antagonistic molecule that enhances the inhibitory activity of sgp130. Furthermore, in combination with sIL-6R, sgp130 is a promising candidate for the development of IL-6 antagonists. *The Journal of Immunology*, 1998, 161: 6347–6355.

# Outline: Interleukin-6 signal transduction and its regulation

## Part 1: Molecular mechanisms of IL-6 signal transduction

## Part 2: Regulation of IL-6 signal transduction

- Half-lives of the signaling components
- Polar expression of IL-6 receptor- $\alpha$  (gp80)
- IL-6 receptor- $\alpha$  shedding
- **Internalization of the ligand/IL-6 receptor complex (desensitization)**
- Phosphotyrosine-phosphatase SHP2 deactivates receptors, JAKs and STAT3
- SOCS proteins (suppressors of cytokine signaling) are feedback inhibitors
- Protein inhibitors of activated STATs (PIAS)
- Cross-talks between JAK/STAT signaling and proinflammatory cytokines (IL-1, TNF $\alpha$ )
  - STAT3 and NF- $\kappa$ B compete for an overlapping response element
  - IL-1 stabilizes SOCS3-mRNA
  - IL-1 accelerates the internalization of the signal transducer gp130


# A Di-leucine Motif and an Upstream Serine in the Interleukin-6 (IL-6) Signal Transducer gp130 Mediate Ligand-induced Endocytosis and Down-regulation of the IL-6 Receptor\*

145 citations (07/2022)

(Received for publication, August 31, 1995, and in revised form, December 4, 1995)

**Elke Dittrich‡, Carol Renfrew Haft§, Leon Muys¶, Peter C. Heinrich‡, and Lutz Graeve‡||**

*From the ‡Institute of Biochemistry, Rheinisch-Westfälische Technische Hochschule Aachen, 52057 Aachen, Germany, the §Diabetes Branch, NIDDKD, National Institutes of Health, Bethesda, Maryland 20892-1770, and the ¶Institute of Pathology, Rheinisch-Westfälische Technische Hochschule Aachen, 52057 Aachen, Germany*




# Intracellular domain of gp130



tm transmembrane domain



Internalization of monoclonal antibodies B-R3 and B-S12 by  
COS-7 cells expressing gp130AA or gp130




# Outline: Interleukin-6 signal transduction and its regulation

## Part 1: Molecular mechanisms of IL-6 signal transduction


## Part 2: Regulation of IL-6 signal transduction

- Half-lives of the signaling components
- Polar expression of IL-6 receptor- $\alpha$  (gp80)
- IL-6 receptor- $\alpha$  shedding
- Internalization of the ligand/IL-6 receptor complex (desensitization)
- **Phosphotyrosine-phosphatase SHP2 deactivates receptors, JAKs and STAT3**
- SOCS proteins (suppressors of cytokine signaling) are feedback inhibitors
- Protein inhibitors of activated STATs (PIAS)
- Cross-talks between JAK/STAT signaling and proinflammatory cytokines (IL-1, TNF $\alpha$ )
  - STAT3 and NF- $\kappa$ B compete for an overlapping response element
  - IL-1 stabilizes SOCS3-mRNA
  - IL-1 accelerates the internalization of the signal transducer gp130

The IL-6 / JAK / STAT signaling cascade is well controlled




The IL-6 / JAK / STAT signaling cascade is well controlled






The IL-6 / JAK / STAT signaling cascade is well controlled



# Inhibition of IL-6 signaling through SHP2

SHP2 = SH2-containing Phosphatase 2



Schaper et al. *Biochem J* 1998

141 citations (07/2022)

Anhuf et al. *J Immunol* 2000

41 citations (07/2022)

Lehmann et al. *J Biol Chem* 2003


184 citations (07/2022)

Clahsen et al. *Cell Signal* 2005

16 citations (07/2022)

# Inhibition of IL-6 signaling through SHP2

SHP2 = SH2-containing Phosphatase 2



Schaper et al. *Biochem J* 1998

141 citations (07/2022)

Anhuf et al. *J Immunol* 2000

41 citations (07/2022)

Lehmann et al. *J Biol Chem* 2003

184 citations (07/2022)


Clahsen et al. *Cell Signal* 2005

16 citations (07/2022)


gene expression

# Inhibition of IL-6 signaling through SHP2

SHP2 = *SH2-containing Phosphatase 2*




# Receptor-targeted SHP2 counteracts gp130-dependent gene induction





HepG2

# SHP2 counteracts gp130-mediated signal transduction



murine embryonic fibroblasts



# Affinities of SOCS3 and SHP2 to murine pY757-gp130 peptide



	$K_D$ [nM]
SHP2-SH2 (N)	1200
SHP2-SH2 (C)	550
SHP2-SH2 (N) + SH2 (C)	170
SOCS3 full length	42
SOCS3-SH2-domain	140

**KIR** Kinase Inhibitory Region  
**SH2** Src Homology 2  
**ESS** Extended SH2 Subdomain

# Outline: Interleukin-6 signal transduction and its regulation

## Part 1: Molecular mechanisms of IL-6 signal transduction

## Part 2: Regulation of IL-6 signal transduction

- Half-lives of the signaling components
- Polar expression of IL-6 receptor- $\alpha$  (gp80)
- IL-6 receptor- $\alpha$  shedding
- Internalization of the ligand/IL-6 receptor complex (desensitization)
- Phosphotyrosine-phosphatase SHP2 deactivates receptors, JAKs and STAT3
- **SOCS proteins (suppressors of cytokine signaling) are feedback inhibitors**
- Protein inhibitors of activated STATs (PIAS)
- Cross-talks between JAK/STAT signaling and proinflammatory cytokines (IL-1, TNF $\alpha$ )
  - STAT3 and NF- $\kappa$ B compete for an overlapping response element
  - IL-1 stabilizes SOCS3-mRNA
  - IL-1 accelerates the internalization of the signal transducer gp130



1997

**SOCS proteins (suppressors of cytokine signaling) were independently discovered in 3 different laboratories.**

### **A new protein containing an SH2 domain that inhibits JAK kinases**

**Takaho A. Endo<sup>††</sup>, Masaaki Masuhara<sup>††</sup>, Masahiro Yokouchi<sup>††‡</sup>, Ritsu Suzuki<sup>†‡</sup>, Hiroshi Sakamoto<sup>\*</sup>, Kaoru Mitsui<sup>\*</sup>, Akira Matsumoto<sup>\*</sup>, Shyu Tanimura<sup>\*</sup>, Motoaki Ohtsubo<sup>\*</sup>, Hiroyuki Misawa<sup>\*</sup>, Tadaaki Miyazaki<sup>§</sup>, Nogueira Leonor<sup>§</sup>, Tadatsugu Taniguchi<sup>§</sup>, Takashi Fujita<sup>||</sup>, Yuzuru Kanakura<sup>†</sup>, Seturo Komiya<sup>‡</sup> & Akihiko Yoshimura<sup>\*</sup>**

<sup>\*</sup> Institute of Life Science, and <sup>‡</sup> Department of Orthopedic Surgery, Kurume University, Aikawamachi 2432-3 Kurume 839, Japan  
<sup>§</sup> Department of Immunology, Faculty of Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113, Japan

**Nature volume 387**, pages 921–924  
Citations 1184 (07/2022)

### **A family of cytokine-inducible inhibitors of signalling**

**Robyn Starr<sup>\*</sup>, Tracy A. Willson<sup>\*</sup>, Elizabeth M. Viney<sup>\*</sup>, Leecia J. L. Murray<sup>\*</sup>, John R. Rayner<sup>†</sup>, Brendan J. Jenkins<sup>†</sup>, Thomas J. Gonda<sup>†</sup>, Warren S. Alexander<sup>\*</sup>, Donald Metcalf<sup>\*</sup>, Nicos A. Nicola<sup>\*</sup> & Douglas J. Hilton<sup>\*</sup>**

<sup>\*</sup> The Walter and Eliza Hall Institute for Medical Research and The Cooperative Research Center for Cellular Growth Factors, Parkville, Victoria, Australia 3052  
<sup>†</sup> The Hanson Centre for Cancer Research, IMVS, Adelaide, Southern Australia, Australia 5000

**Nature volume 387**, pages 917–921  
Citations 1727 (07/2022)


### **Structure and function of a new STAT-induced STAT inhibitor**

**Tetsuji Naka<sup>\*</sup>, Masashi Narazaki<sup>\*</sup>, Moritoshi Hirata<sup>\*</sup>, Tomoshige Matsumoto<sup>\*</sup>, Seiji Minamoto<sup>\*</sup>, Atsufumi Aono<sup>\*</sup>, Norihiro Nishimoto<sup>†</sup>, Tadahiro Kajita<sup>‡</sup>, Tetsuya Taga<sup>§</sup>, Kazuyuki Yoshizaki<sup>†</sup>, Shizuo Akira<sup>||</sup> & Tadamitsu Kishimoto<sup>\*</sup>**

<sup>\*</sup> Osaka University Medical School Department of Medicine III. 2-2, Yamada-Oka, Suita, Osaka 565, Japan


**Nature volume 387**, pages 924–929  
Citations 1096 (07/2022)

# The SOCS (SUPPRESSORS OF CYTOKINE SIGNALING) family



# Inhibition through SOCS-feedback inhibitors

SOCS=Suppressor of Cytokine Signaling



Schmitz et al. *J Biol Chem* 2000

319 citations (07/2022)

Friederichs et al. *Eur J Biochem* 2001


23 citations (07/2022)

Fischer et al. *Biochem J* 2004

58 citations (07/2022)

# Inhibition through SOCS-feedback inhibitors

SOCS=Suppressor of Cytokine Signaling



Schmitz et al. *J Biol Chem* 2000

319 citations (07/2022)

Friederichs et al. *Eur J Biochem* 2001


23 citations (07/2022)

Fischer et al. *Biochem J* 2004

58 citations (07/2022)

# Inhibition through SOCS-*feedback* inhibitors

SOCS=Suppressor of Cytokine Signaling



Schmitz et al. *J Biol Chem* 2000

319 citations (07/2022)

Friederichs et al. *Eur J Biochem* 2001


23 citations (07/2022)

Fischer et al. *Biochem J* 2004

58 citations (07/2022)



# Inhibition through SOCS-*feedback* inhibitors

SOCS=Suppressor of Cytokine Signalling



# SOCS3 binds the phosphotyrosine motif 759 of gp130

binding to gp130 phospho-peptides (13-mers)



COS7 cells


- SOCS1 inhibits *via* direct binding to JAKs
- SOCS3 inhibits *via* receptor binding




# SOCS3-mediated signal attenuation is SHP2-independent

gene induction

SHP2 wt



SHP2 mut



# SOCS3 Exerts Its Inhibitory Function on Interleukin-6 Signal Transduction through the SHP2 Recruitment Site of gp130\*

(Received for publication, May 27, 1999, and in revised form, January 19, 2000)

Jochen Schmitz, Manuela Weissenbach, Serge Haan, Peter C. Heinrich‡, and Fred Schaper

From the Institut für Biochemie, Rheinisch-Westfälische Technische Hochschule Aachen, Pauwelsstraße 30, D-52074 Aachen, Germany

319 citations (07/2022)

# SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130\*

Received for publication, October 15, 2002

Published, JBC Papers in Press, October 27, 2002, DOI 10.1074/jbc.M210552200


Ute Lehmann‡§, Jochen Schmitz‡§, Manuela Weissenbach‡, Radoslaw M. Sobota‡, Michael Hörtnert¶, Kerstin Friederichs‡, Iris Behrmann‡, William Tsiaris||, Atsuo Sasaki\*\*, Jens Schneider-Mergener‡‡, Akihiko Yoshimura\*\*, Benjamin G. Neel||, Peter C. Heinrich‡§§, and Fred Schaper‡§§

Jochen Schmitz as a post-doc at DNAX cloned IL-33


184 citations (07/2022)




The JAK/STAT signalling cascade is well controlled



# The JAK/STAT signalling cascade is well controlled



# The JAK/STAT signalling cascade is well controlled




# Outline: Interleukin-6 signal transduction and its regulation

## Part 1: Molecular mechanisms of IL-6 signal transduction

## Part 2: Regulation of IL-6 signal transduction

- Half-lives of the signaling components
- Polar expression of IL-6 receptor- $\alpha$  (gp80)
- IL-6 receptor- $\alpha$  shedding
- Internalization of the ligand/IL-6 receptor complex (desensitization)
- Phosphotyrosine-phosphatase SHP2 deactivates receptors, JAKs and STAT3
- SOCS proteins (suppressors of cytokine signaling) are feedback inhibitors
- **Protein inhibitors of activated STATs (PIAS)**
- Cross-talks between JAK/STAT signaling and proinflammatory cytokines (IL-1, TNF $\alpha$ )
  - STAT3 and NF- $\kappa$ B compete for an overlapping response element
  - IL-1 stabilizes SOCS3-mRNA
  - IL-1 accelerates the internalization of the signal transducer gp130

PIAS3 exerts a profound inhibitory effect on STAT3-mediated transcription of target promoters, the zinc finger protein Gfi-1 can overcome the PIAS3 block





The EMBO Journal Vol. 19 No. 21 pp. 5845–5855, 2000

2000

# The zinc finger protein Gfi-1 can enhance STAT3 signaling by interacting with the STAT3 inhibitor PIAS3

114 citations (07/2022)



**Bernd Rödel, Kamiab Tavassoli,  
Holger Karsunky, Thorsten Schmidt<sup>1</sup>,  
Malte Bachmann, Fred Schaper<sup>2</sup>,  
Peter Heinrich<sup>2</sup>, Ke Shuai<sup>3</sup>,  
Hans Peter Elsässer<sup>4</sup> and Tarik Möröy<sup>5</sup>**

Institut für Zellbiologie (Tumorforschung), IFZ, Universitätsklinikum Essen, Virchowstrasse 173, D-45122 Essen, <sup>1</sup>Bayer AG, Apratherweg 18a, D-42096 Wuppertal, <sup>2</sup>Institut für Biochemie, Universitätsklinikum, RWTH Aachen, Pauwelsstrasse 30, D-52074 Aachen, <sup>4</sup>Institut für Zytobiologie und Zytopathologie, Philipps Universität Marburg, D-35033 Marburg, Germany and <sup>3</sup>Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA, USA

<sup>5</sup>Corresponding author  
e-mail: moeroey@uni-essen.de

B.Rödel and K.Tavassoli contributed equally to this work

The Zn-finger protein Gfi relieves the PIAS3-mediated block of STAT3-induced  $\alpha$ 1-antichymotrypsin gene activation




# Outline: Interleukin-6 signal transduction and its regulation

## Part 1: Molecular mechanisms of IL-6 signal transduction


## Part 2: Regulation of IL-6 signal transduction

- Half-lives of the signaling components
- Polar expression of IL-6 receptor- $\alpha$  (gp80)
- IL-6 receptor- $\alpha$  shedding
- Internalization of the ligand/IL-6 receptor complex (desensitization)
- Phosphotyrosine-phosphatase SHP2 deactivates receptors, JAKs and STAT3
- SOCS proteins (suppressors of cytokine signaling) are feedback inhibitors
- Protein inhibitors of activated STATs (PIAS)
- **Cross-talks between JAK/STAT signaling and proinflammatory cytokines (IL-1, TNF $\alpha$ )**
  - **STAT3 and NF- $\kappa$ B compete for an overlapping response element**
  - **IL-1 stabilizes SOCS3-mRNA**
  - **IL-1 accelerates the internalization of the signal transducer gp130**


# IL-1 $\beta$ inhibits IL-6-induced $\alpha_2$ macroglobulin synthesis in rat hepatocytes




# How does IL-1 $\beta$ affect IL-6-mediated signaling?



# How does IL-1 $\beta$ affect IL-6-mediated signaling?





# Interleukin-1-signal transduction




IL, Interleukin  
 IL-1RI Interleukin-1-receptor  
 TIR toll-like/Interleukin-1-receptor  
 IL-1RAcP Interleukin-1-receptor accessory protein  
 MyD88, myeloid differentiation (88 kDa)  
 DD death domain  
 IRAK, IL-1 receptor associated kinase  
 TRAF, TNF receptor associated factor  
 TAK, TGF-β activated kinase  
 TAB, TAK binding protein  
 IKK, IκB- kinase  
 IκB, Inhibitor of NF-κB  
 NF-κB, nuclear factor κB  
 Ub, Ubiquitin



# IL-1 $\beta$ inhibits $\alpha_2$ M-promoter-activity via NF- $\kappa$ B activation




HepG2






# NF- $\kappa$ B and STAT3 bind to the $\alpha_2$ M-promoter

anti-p65	-	-	-	+	-	-	+
anti-STAT3	-	-	+	-	-	+	-
IL-6	-	+	+	+	+	+	+
IL-1 $\beta$	-	-	-	-	+	+	+




IL-6	-	+	+	+	+	+	+
p50	-	-					






# NF- $\kappa$ B and STAT3 bind to the $\alpha_2$ M-promoter


anti-p65	-	-	-	+	-	-	+
anti-STAT3	-	-	+	-	-	+	-
IL-6	-	+	+	+	+	+	+
IL-1 $\beta$	-	-	-	-	+	+	+



IL-6	-	+	+	+	+	+	+
p50	-	-					



# The $\alpha_2$ -Macroglobulin Promotor



**STAT3 and NF-  $\kappa$ B compete for an overlapping response element**

**The Inhibitory Effect of IL-1 $\beta$  on IL-6-Induced  $\alpha_2$ -Macroglobulin Expression Is Due to Activation of NF- $\kappa$ B<sup>1</sup>**

*Journal of Immunology*, 2001, 167:1469-1481

Johannes G. Bode,<sup>2\*</sup> Richard Fischer,<sup>†</sup> Dieter Häussinger,<sup>†</sup> Lutz Graeve,<sup>\*</sup> Peter C. Heinrich,<sup>3\*</sup> and Fred Schaper<sup>\*</sup> [43 citations](#) (07/2022)